Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
NCT05530785
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
COMBINATION_PRODUCT:
radiotherapy combined with sintilimab and bevacizumab biosimilar
Sponsor
Yongchang Zhang